Immuneering (IMRX) Net Equity Issued and Repurchased (2020 - 2025)

Immuneering's Net Equity Issued and Repurchased history runs 5 years deep, the most recent figure standing at $1081.0 for Q4 2025.

• In Q4 2025, Net Equity Issued and Repurchased fell 97.11% year-over-year to $1081.0; the TTM figure through Mar 2026 stood at $1.3 million (down 92.74% YoY), while the FY2025 annual figure was $25.0 million, up 489.98% from the prior year.
• Net Equity Issued and Repurchased for Q4 2025 stood at $1081.0, down from $1.3 million in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $95.5 million in Q3 2021, with the low at -$28.2 million in Q4 2023.
• The 4-year median for Net Equity Issued and Repurchased is $1.3 million (2025), against an average of $12.4 million.
• The sharpest annual moves came in 2024 and 2025: Net Equity Issued and Repurchased jumped 100.13% in 2024, then slumped 97.11% in 2025.
• Immuneering's Net Equity Issued and Repurchased stood at $95.5 million in 2021, then slumped by 129.52% to -$28.2 million in 2023, then jumped by 100.13% to $37397.0 in 2024, then plunged by 97.11% to $1081.0 in 2025.
• Business Quant data shows IMRX's Net Equity Issued and Repurchased at $1081.0 in Q4 2025, $1.3 million in Q3 2025, and $13.7 million in Q1 2025.